Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Jun. 30, 2016 | Jul. 03, 2016 | |
Document And Entity Information | ||
Entity Registrant Name | Rich Pharmaceuticals, Inc. | |
Entity Central Index Key | 1,504,389 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2016 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --03-31 | |
Is Entity a Well-known Seasoned Issuer? | No | |
Is Entity a Voluntary Filer? | No | |
Is Entity's Reporting Status Current? | No | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 447,369,610 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2,016 |
Condensed Balance Sheets
Condensed Balance Sheets - USD ($) | Jun. 30, 2016 | Mar. 31, 2016 |
Current Assets | ||
Cash and equivalents | ||
Prepaid expenses | 2,800 | 2,800 |
Total Current Assets | 2,800 | 2,800 |
Property and equipment, net | 3,300 | 3,731 |
TOTAL ASSETS | 6,100 | 6,531 |
Current Liabilities | ||
Bank overdraft | 1,942 | 2,948 |
Accounts payable | 1,154,821 | 1,139,431 |
Accrued expenses | 627,970 | 530,150 |
Due to related parties | 39,138 | 76,913 |
Convertible notes payable, net of debt discount | 371,641 | 201,879 |
Derivative liabilities | 322,214 | 446,912 |
Total Current Liabilities | 2,517,726 | 2,398,233 |
Long-term Liabilities | ||
Convertible notes payable, net of debt discount | ||
Derivative liabilities | ||
Total Long-term Liabilities | ||
Total Liabilities | 2,517,726 | 2,398,233 |
Stockholders Deficit | ||
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively | 6,000 | 6,000 |
Common stock, $0.001 par value, 4,000,000,000 shares authorized, 447,369,610 and 216,364,262 shares issued and outstanding, | 447,370 | 216,364 |
Additional paid-in capital | 6,416,805 | 6,589,374 |
Accumulated deficit | (9,381,801) | (9,203,440) |
Total Stockholders Deficit | (2,511,626) | (2,391,702) |
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | $ 6,100 | $ 6,531 |
Condensed Balance Sheets (Paren
Condensed Balance Sheets (Parenthetical) - $ / shares | Jun. 30, 2016 | Mar. 31, 2016 | Sep. 06, 2013 | Sep. 05, 2013 |
Statement of Financial Position [Abstract] | ||||
Common Stock, Par Value | $ .001 | $ .001 | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 4,000,000,000 | 4,000,000,000 | 375,030,000 | 900,000 |
Common Stock, Issued | 447,369,610 | 216,364,262 | ||
Preferred Stock, Par Value | $ .001 | $ .001 | ||
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | ||
Preferred Stock, Issued | 6,000,000 | 6,000,000 |
Condensed Statements of Operati
Condensed Statements of Operations - USD ($) | 3 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | |
Income Statement [Abstract] | ||
REVENUES | ||
OPERATING EXPENSES | ||
Consulting expenses | 10,225 | 6,000 |
Office expenses | 34,574 | 20,753 |
Depreciation expense | 431 | 118 |
Wages and taxes | 95,954 | 91,723 |
Professional fees | 54,243 | 65,947 |
Regulatory fees | 6,843 | 1,669 |
Research and development | 7,000 | |
Stock-based compensation | 130,091 | |
Travel, meals and entertainment | 13,205 | 2,612 |
TOTAL OPERATING EXPENSES | 215,475 | 325,913 |
LOSS FROM OPERATIONS | (215,475) | (325,913) |
OTHER INCOME (EXPENSE) | ||
Amortization of debt discount | (46,573) | (165,629) |
Change in value of derivative liability | 116,771 | 48,413 |
Derivative expense | (191,844) | |
Interest expense | (33,009) | (12,696) |
Interest expense related party | (75) | (74) |
Other Income Total | 37,114 | (321,830) |
LOSS BEFORE PROVISION FOR INCOME TAXES | (178,361) | (647,743) |
PROVISION FOR INCOME TAXES | ||
NET LOSS | $ (178,361) | $ (647,743) |
NET LOSS PER SHARE: BASIC AND DILUTED | $ 0 | $ (0.03) |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED | 321,411,329 | 21,257,881 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows - USD ($) | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | Mar. 31, 2016 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |||
Net loss for the period | $ (178,361) | $ (647,743) | |
Adjustments to reconcile net loss to net cash used in operating activities | |||
Depreciation expense | 431 | 118 | $ 799 |
Amortization of debt discount | 46,573 | 165,629 | |
Change in value of derivative liability | (116,771) | (48,413) | |
Derivative expense | (191,844) | ||
Interest converted into stock | 3,449 | ||
Warrants issued for services | 13,259 | ||
Stock-based compensation | 130,091 | ||
Changes in operating assets and liabilities: | |||
(Increase) decrease in prepaid expenses | 2,743 | ||
Decrease in bank overdraft | (1,006) | ||
Increase in accounts payable | 15,390 | 5,303 | |
Increase (decrease) in accrued expenses | 97,820 | 45,524 | |
Net Cash Used by Operating Activities | (132,475) | (141,645) | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Loans and interest received (repaid) | 74 | ||
Loans received (repaid) from/to related parties | (37,775) | ||
Proceeds from sale of common stock and warrants | 29,462 | ||
Proceeds from issuance of convertible notes payable | 170,250 | 96,307 | |
Net Cash Provided by Financing Activities | 132,475 | 125,843 | |
Net Increase (Decrease) in Cash and Cash Equivalents | (15,802) | ||
Cash and cash equivalents, beginning of period | 15,892 | 15,892 | |
Cash and cash equivalents, end of period | 90 | ||
SUPPLEMENTAL CASH FLOW INFORMATION: | |||
Interest paid | |||
Income taxes paid | |||
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION: | |||
Original issue discounts recorded on notes payable | 11,531 | ||
Debt discounts recorded on convertible notes payable | |||
Debt/interest converted into common stock | $ 50,510 | $ 449,825 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Jun. 30, 2016 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (Rich or the Company). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series A Preferred Stock. Our Series A Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the Assignment Agreement) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled Phorbol esters as anti-neoplastic and white blood cell elevating agents and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series A Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the Sale Agreement) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At June 30, 2016 and March 31, 2016 the Company had $0 and $0, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets. ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the assets carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair Value of Financial Instruments The Companys financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companys assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 Observable inputs such as quoted prices in active markets; Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at June 30, 2016 or March 31, 2015. As of June 30, 2016, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Research and Development The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Companys net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Companys net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Companys results of operations, financial position or cash flow. |
Property and equipment
Property and equipment | 3 Months Ended |
Jun. 30, 2016 | |
Property, Plant and Equipment [Abstract] | |
Property and equipment | Property and equipment, recorded at cost, consisted of the following as of June 30, 2016 and March 31, 2016: June 30, 2016 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (1,860 ) (1,429 ) Property and equipment, net $ 3,300 $ 3,731 The useful life of the computer equipment and furniture is 3 years. Depreciation expense was $431 and $799 for the periods ended June 30, 2016 and March 31, 2016, respectively . |
Intangible Assets
Intangible Assets | 3 Months Ended |
Jun. 30, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | On July 18, 2013, the Company entered into an Asset Assignment Agreement (the Assignment Agreement) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled Phorbol esters as anti-neoplastic and white blood cell elevating agents and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series A Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the Assignment Agreement) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled Compositions and methods of use of Phorbol Esters for the treatment of Hodgkins Lymphoma, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. |
Accrued Expenses
Accrued Expenses | 3 Months Ended |
Jun. 30, 2016 | |
Payables and Accruals [Abstract] | |
Accrued Expenses | Accrued expenses consisted of the following as of June 30, 2016 and March 31, 2016: June 30, 2016 March 31, 2016 Wages and taxes $ 608,468 $ 514,713 Accrued interest 19,502 15,437 Total accrued expenses $ 627,970 $ 530,150 |
Related Party Debt and Transact
Related Party Debt and Transactions | 3 Months Ended |
Jun. 30, 2016 | |
Related Party Transactions [Abstract] | |
Related Party Debt and Transactions | On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the Sale Agreement) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015. Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended June 30, 2016 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest. There is a total due of $12,280 as of June 30, 2016. Interest accrued on the note as of June 30, 2016 was $442. The Company is in default on the balance of this note. During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending June 30, 2016 received an additional $3,100, and has repaid $24,009 of these loans leaving a total due of $1,291 as of June 30, 2016. These loans are deemed to be short-term and are payable at the discretion of the Company. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 30,002 shares of common stock at an exercise price of $2.00 per share. The CEO earned $68,749 and $275,000 for the periods ended June 30, 2016 and March 31, 2016 (respectively) as a result of this agreement, these amounts contribute to the $462,612 and $395,630 of officer compensation which is included in accrued expenses, as of June 30, 2016 and March 31, 2016. |
Stock Deposits
Stock Deposits | 3 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
Stock Deposits | The Company received deposits for future stock purchases during the year ended March 31, 2014 totaling $147,050. The Company signed subscription agreements with four investors on June 16, 2014 to grant 14,690 shares of common stock in exchange for the deposits. The remaining balance as of June 30, 2016 and March 31, 2016 is $0. |
Convertible Note Payable
Convertible Note Payable | 3 Months Ended |
Jun. 30, 2016 | |
Debt Disclosure [Abstract] | |
Convertible Note Payable | On March 11, 2014, the Company issued a convertible promissory note in the amount of $37,500. The note is due on December 13, 2014 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $37,500 of principal and $1,500 of interest into 21,593 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On April 8, 2014, the Company issued a convertible note payable in the amount of $53,000. The note bears 8% interest and is due on January 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date . On May 21, 2014, the Company issued a convertible note payable in the amount of $42,500. The note bears 8% interest and is due on February 23, 2015. The note is currently in default. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $42,500 of principal and $1,700 of interest into 152,524 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $3,380. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $66,780 of principal and $2,850 of interest into 1,214,425 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $58,300 of principal and $2,527 of interest into 1,310,912 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 177,836 shares of common stock leaving a remaining balance of accrued interest of $0. On August 19, 2014, the Company issued a convertible note payable in the amount of $57,895 including an original issue discount of $2,895. The note bears 12% interest and is due on August 19, 2016. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $57,895 of principal and $14,035 of interest (including a $10,000 penalty) into 1,798,250 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2016. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2016. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2016. On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2016. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2016. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2016. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of June 30, 2016 is $5,156. The Company is in default on the balance of this note. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2016. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2016. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 46,484,586 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2016. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,939 in principal and $707 in accrued interest into 30,988,380 shares of common stock leaving a remaining balance of $52,500. Accrued interest was $4,860 as of June 30, 2016 . On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of June 30, 2016. The Company is in default on the balance of this note. On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending June 30, 2016 the note holder converted $15,000 in principal and $939 in accrued interest into 87,032,383 shares of common stock leaving a remaining balance of $0. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of June 30, 2016 is $19,000, and On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016 , The loan becomes convertible on , 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1.609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of June 30, 2016 is $2,652. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $5,315 in principal into 11,682,000 shares of common stock. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of June 30, 2016 is $406. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of June 30, 2016 is $86. |
Derivative Liabilities
Derivative Liabilities | 3 Months Ended |
Jun. 30, 2016 | |
Notes to Financial Statements | |
Derivative Liabilities | In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending June 30, 2016 and March 31, 2016: $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $33,000 note dated January 9, 2015; $54,000 note dated February 5, 2015; $66,780 note dated February 17, 2015;$58,300 note dated March 2, 2015; $55,000 note dated March 9, 2015; $29,680 note dated March 26, 2015; $68,900 note dated May 5, 2015; $10,500 note dated May 6, 2015; $16,500 note dated May 27, 2015; $15,000 note dated August 28, 2015; $19,000 note dated September 4, 2015; $55,000 note dated December 29, 2015; $60,500 note dated January 22, 2016; $27,500 note dated February 25, 2016; $7,500 note dated March 24, 2016; $30,000 note dated May 25, 2016; $84,250 note dated June 8, 2016; and a $56,000 note dated June 23, 2016. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Companys only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended June 30, 2016, the Company recorded a total change in the fair market value of the derivative liabilities of $116,771. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0004, exercise price of $0.00022 - $0.0003, dividend yield of zero, years to maturity of 0.10137 .9808, a risk free rate of 0.26% - 0.45%, and annualized volatility of 352% - 452%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370, the May 5, 2015 loan which had an initial debt discount of $41,222, and the May 27, 2015 loan which had an initial debt discount of $15,000. Based on the valuations on the initial valuation dates for the period ending June 30, 2016, the Company recognized debt discounts related to the conversion features totaling $0 and a derivative expense of $0 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of June 30, 2016, unamortized debt discount, including original issue discounts totaled $41,792. The derivative liabilities totaled $322,214 as of June 30, 2016, of which $0 related to long-term debt. |
Equity Transactions
Equity Transactions | 3 Months Ended |
Jun. 30, 2016 | |
Equity Transactions | |
Equity Transactions | The Company has 4,000,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series A Preferred Stock. The Series A Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series A Preferred shares and 827,670 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 5,002,554 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares from 900,000 to 375,030,000. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On March 10, 2014, the Company issued 833 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 2,500 2,500 833 Stock price on grant date $30.00 $2.00 $2.00 Exercise price $50.00 $50.00 $50.00 Expected life 1 year 1 year 1 year Volatility 147% 64% 65% Risk-free rate 0.12% 0.11% 0.13% Calculated value $10,473 $0 $0 Fair value allocation of proceeds $7,381 $0 $0 On April 4, 2014, the Company issued 833 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On April 24, 2014, the Company issued 10,000 units at $25.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $35.00 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 10, 2014, the Company issued 7,000 units at $4.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $15.00 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 29, 2014, the Company issued 7,000 units at $5.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $15.00 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On June 9, 2015, the Company issued 900,000 units at $0.02 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.02 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 15, 2015, the Company issued 4,000,000 units at $0.01 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.01 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 June 9, 2015 Dec 15,2015 Warrants 833 10,000 7,000 7,000 900,000 4,000,000 Stock price on grant date $19.90 $25.20 $3.70 $3.70 $0.02 $0.01 Exercise price $50.00 $35.00 $15.00 $15.00 $0.02 $0.01 Expected life 1 year 3 year 3 year 3 year 5 year 5 year Volatility 113% 76% 119% 119% 98% 98% Risk-free rate 0.12% 0.84% 0.96% 0.98% 1.74% 1.71% Calculated value $3,181 $104,416 $12,130 $12,102 $13,259 $29,612 Fair value allocation of proceeds $2,822 $73,653 $8,637 $8,992 $13,259 $29,612 The following is a summary of the warrant activity for the period from April 1, 2013 to June 30, 2016: Number of warrants Weighted average exercise price Outstanding, March 31, 2014 5,833 $50.00 Granted 24,833 $24.00 Exercised - - Outstanding, March 31, 2015 30,666 $29.00 Granted 4,900,000 $0.012 Exercised - - Outstanding, June 30, 2016 4,930,666 $0.192 On May 7, 2014, the Company granted 25,000 shares to a consultant for prior services rendered. The Company had accrued $300,000 for these services as of March 31, 2014. On June 16, 2014, the Company issued 14,690 shares of common stock for stock deposits of $147,050. The Company had received the deposits during the year ended March 31, 2014. On July 1, 2014, the Company granted 10,000 shares to a professional for prior legal services rendered. The Company had accrued $30,000 for these services as of June 30, 2014. The shares were valued on the grant date at the fair market value of $60,000 resulting in a loss on the issuance of shares of $30,000. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the Assignment Agreement) with Imagic, LLC, a related party, and its principals to acquire certain assets including a US Patent entitled Compositions and methods of use of Phorbol Esters for the treatment of Hodgkins Lymphoma, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value of $7,822,235 as a deemed dividend reducing additional paid in capital. Also on October 6, 2014, the Board of Directors approved the issuance of 80,000 shares of common stock to the CEO and 40,000 shares of common stock to the Companys attorney as bonuses. The shares were valued based on the closing stock price on the grant date for a total value of $429,600. On November 19, 2014, the Company entered into an agreement with an unrelated vendor to provide six months of consulting services in exchange for 5,000 shares of common stock. The shares were valued based on the closing stock price on the grant date for a total value of $6,450. The entire contract was expensed as of March 31, 2015. On August 13, 2014, the Company entered into an investment agreement with an investor to invest up to $4,000,000 to purchase the Companys common stock. The price per share for each investment is determined by the lesser of: (1) 65% of the lowest traded price of the Companys common stock during the ten consecutive trading days prior to the drawdown notice date or (2) 65% of the closing bid price on the day before the drawdown notice is submitted. During the year ended March 31, 2015, the Company issued 799,619 shares of common stock to this investor for total proceeds of $220,000. On April 22, 2015, the Company sold 100,381 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable. On June 25, 2015, the Company sold 1,542,455 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company. On July 7, 2015, the Company sold 1,619,423 shares of common stock for $11,336 in cash, of which $3,750 was paid directly to a vendor for professional services. On July 15, 2015, the Company sold 1,439,282 shares of common stock for $10,075 in cash. On October 27, 2015, the Company sold 1,648,840 shares of common stock for $11,542 in cash. During the periods ended June 30, 2016, March 31, 2016 and 2015, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $ 12,000 5,505 $ 2.18 October 1, 2014 $ 12,000 6,487 $ 1.85 October 8, 2014 $ 9,000 5,056 $ 1.78 October 16, 2014 $ 6,000 4,546 $ 1.32 October 29, 2014 $ 15,000 12,500 $ 1.20 November 3, 2014 $ 10,000 8,197 $ 1.22 November 7, 2014 $ 12,000 11,881 $ 1.01 November 19, 2014 $ 18,120 28,312 $ 0.64 December 8, 2014 $ 15,000 34,884 $ 0.43 December 15, 2014 $ 12,000 42,857 $ 0.28 December 26, 2014 $ 17,200 74,783 $ 0.23 February 11, 2015 $ 29,900 747,500 $ 0.04 February 12, 2015 $ 17,333 373,561 $ 0.046 February 13, 2015 $ 17,894 372,800 $ 0.048 February 15, 2015 $ 35,730 739,243 $ 0.048 February 17, 2015 $ 17,003 366,440 $ 0.046 February 23, 2015 $ 20,603 470,900 $ 0.044 February 23, 2015 $ 17,003 366,440 $ 0.046 February 24, 2015 $ 9,488 204,473 $ 0.046 February 26, 2015 $ 42,030 1,050,750 $ 0.040 February 27, 2015 $ 26,880 560,000 $ 0.048 March 2, 2015 $ 56,402 1,215,551 $ 0.046 March 9, 2015 $ 33,900 475,182 $ 0.071 March 10, 2015 $ 25,200 700,000 $ 0.036 March 20, 2015 $ 10,000 181,818 $ 0.006 March 31, 2015 Total $ 498,686 8,059,666 On February 8, 2016, the Company approved a change in the authorized shares of common stock to 375,030,000 shares. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values The Company follows ASC Topic 505-50, formerly EITF 96-18, Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services, for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined. During the year ended March 31, 2014, the Company granted 475,033 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 672,533 previously granted options under the Companys 2013 Equity Incentive Plan, which had exercise prices between $1.91984 per share and $30.0 per share, to $0.17 per share which was the closing price of the Companys common stock on January 9, 2015. All of the other terms of the options remained unchanged. Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $ 16,650 411,111 $ 0.04050 April 6, 2015 $ 10,000 209,644 $ 0.04770 April 8, 2015 $ 15,309 453,561 $ 0.03375 April 8, 2015 $ 20,001 454,545 $ 0.04400 April 9, 2015 $ 14,320 325,455 $ 0.04400 April 14, 2015 $ 10,000 236,967 $ 0.04220 April 16, 2015 $ 1,918 53,000 $ 0.03619 April 21, 2015 $ 10,000 259,740 $ 0.03850 April 29, 2015 $ 15,000 389,610 $ 0.03850 May 4, 2015 $ 5,083 131,464 $ 0.03866 May 12, 2015 $ 28,456 903,380 $ 0.03150 May 20, 2015 $ 20,199 947,645 $ 0.02131 May 20, 015 $ 17,240 783,636 $ 0.02200 May 27, 2015 $ 13,568 701,801 $ 0.01933 May 29, 2015 $ 15,000 882,353 $ 0.01700 June 11, 2015 $ 9,897 942,609 $ 0.01050 June 16, 2015 $ 14,100 1,175,000 $ 0.01200 June 16, 2015 $ 13,565 1,130,417 $ 0.01200 June 22, 2015 $ 7,415 1,235,833 $ 0.00600 June 22, 2015 $ 14,384 2,479,924 $ 0.00580 June 23, 2015 $ 7,752 1,292,000 $ 0.00600 September 16, 2015 $ 7,974 1,772,033 $ 0.00450 September 28, 2015 $ 10,000 1,666,667 $ 0.00600 September 29, 2015 $ 10,620 1,770,000 $ 0.00600 October 7, 2015 $ 2,250 375,000 $ 0.00600 October 7, 2015 $ 8,400 1,400,000 $ 0.00600 October 19, 2015 $ 9,720 1,620,000 $ 0.00600 November 2, 2015 $ 4,424 1,966,124 $ 0.00225 November 23, 2015 $ 10,000 1,666,667 $ 0.00600 November 30, 2015 $ 16,844 2,591,323 $ 0.00650 December 9, 2015 $ 1,746 775,991 $ 0.00225 December 17, 2015 $ 5,332 919,319 $ 0.00580 December 28, 2015 $ 1,341 596,200 $ 0.00225 December 28, 2015 $ 17,700 2,950,000 $ 0.00600 December 28, 2015 $ 14,305 2,384,167 $ 0.00600 December 28, 2015 $ 14,963 2,579,916 $ 0.00580 December 29, 2015 $ 8,395 1,399,167 $ 0.00600 December 29, 2015 $ 7,670 1,278,333 $ 0.00600 December 30, 2015 $ 6,651 2,956,248 $ 0.00225 January 1, 2016 $ 28,500 4,384,615 $ 0.00650 January 4, 2016 $ 19,339 3,223,213 $ 0.00600 January 5, 2016 $ 8,107 3,603,227 $ 0.00225 January 6, 2016 $ 16,070 2,678,333 $ 0.00600 January 6, 2016 $ 16,597 2,861,607 $ 0.00580 February 16 ,2016 $ 1,424 4,220,400 $ 0.00034 February 17, 2016 $ 12,800 8,443,272 $ 0.00152 February 23, 2016 $ 4,640 4,218,182 $ 0.00110 February 23, 2016 $ 3,086 4,200,871 $ 0.00073 February 24, 2016 $ 1,492 4,419,970 $ 0.00034 February 25, 2016 $ 3,000 2,638,987 $ 0.00114 February 25, 2016 $ 4,640 4,218,182 $ 0.00110 March 1, 2016 $ 1,313 5,834,458 $ 0.00022 March 2, 2016 $ 4,600 5,831,643 $ 0.00079 March 2, 2016 $ 1,650 2,586,410 $ 0.00064 March 2, 2016 $ 9,332 11,650,000 $ 0.00080 March 7, 2016 $ 2,799 6,546,292 $ 0.00043 March 11, 2016 $ 1,924 4,147,500 $ 0.00046 March 14, 2016 $ 2,245 7,125,777 $ 0.00032 March 15, 2016 $ 3,329 7,454,098 $ 0.00045 March 15, 2016 $ 5,210 11,450,000 $ 0.00046 March 22, 2016 $ 2,419 8,957,888 $ 0.00027 March 22, 2016 $ 2,367 7,200,486 $ 0.00033 March 22, 2016 $ 5,315 11,682,000 $ 0.00046 March 28, 2016 $ 1,986 8,958,779 $ 0.00022 March 31, 2016 Total $ 602,376 194,603,040 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $ 2,197 9,766,311 $ 0.000225 April 4, 2016 $ 4,847 17,250,000 $ 0.000281 April 7, 2016 $ 1,750 9,722,222 $ 0.000180 April 14, 2016 $ 4,158 19,250,000 $ 0.000216 April 15, 2016 $ 1,318 9,766,222 $ 0.000135 April 26, 2016 $ 1,705 12,629,776 $ 0.000135 May 4, 2016 $ 2,067 9,718,025 $ 0.000213 May 31, 2016 $ 828 4,600,055 $ 0.000180 June 2, 2016 $ 9,120 30,000,000 $ 0.000304 June 2, 2016 $ 4,401 29,340,333 $ 0.000150 June 14, 2016 $ 5,847 29,235,900 $ .0.000200 June 17,2016 $ 5,691 28,456,150 $ 0.000200 June 29, 2016 $ 6,580 21,270,355 $ 0.000309 June 30, 2016 Total $ 50,509 231,005,349 (2) Effective April 6, 2015, the Company approved the re-pricing of all 2,712,535 previously granted options under the Companys 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.17 per share, to $0.08 per share which was the closing price of the Companys common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 3,712,535 previously granted options under the Companys 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.02 per share, to $0.02 per share which was the closing price of the Companys common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date May 7, 2014 July 23, 2014 October 6, 2014 April 6, 2015 June 9, 2015 December 15, 2015 Options 35,000 7,500 155,000 2,040,003 1,000,000 860,000 Stock price grant date $12.00 $6.90 $3.58 $0.08 $0.02 $0.01 Initial Exercise price $12.00 $6.90 $1.91984 $0.08 $0.02 $0.01 Modified Exercise price $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 Expected life 10.00 10.00 5.0 5.0 5.0 5.0 Volatility 73% 88% 101% 99% 99% 84% Risk-free rate 2.56% 2.53% 1.04% 1.31% 1.74% 1.70% Calculated value $315,772 $45,109 $454,798 $120,778 $14,838 $5,736 Modified value $7,164 $1,537 $31,408 $151,221 $16,347 $5,736 The following is a summary of the option activity for the period April 1, 2013 through June 30, 2016: Number of options Weighted average exercise price Outstanding, March 31, 2014 475,033 $0.01 Granted 197,500 $0.01 Exercised - - Expired - - Outstanding, March 31, 2015 672,533 $0.01 Granted 3,900,003 $0.01 Exercised - - Expired - - Outstanding, June 30, 2016 4,572,536 $0.01 |
Commitments and Contigencies
Commitments and Contigencies | 3 Months Ended |
Jun. 30, 2016 | |
Accounting Policies [Abstract] | |
Commitments and Contingencies | The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,800. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Changs Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (Biosuccess), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Changs Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the District Court). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Changs Holdings, LLC, and Ben Chang (the Litigation). The Complaint seeks relief which includes compensatory damages, attorneys fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation. |
Liquidity and Going Concern
Liquidity and Going Concern | 3 Months Ended |
Jun. 30, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Liquidity and Going Concern | The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Companys ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Managements plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Jun. 30, 2016 | |
Accounting Policies [Abstract] | |
Subsequent Events | On June 25, 2016, the Company executed a Confession on Judgement in favor of LG Capital Funding, LLC regarding any event of default occurring under the convertible promissory notes issued by the Company and held by LG Funding, LLC. On July 7, 2016, the Company issued a convertible note payable in the amount of $58,000. The note bears 8% interest and is due on July 7, 2017. The loan becomes convertible 180 days after issuance or January 3, 2017. The loan and any accrued interest can then be converted into shares of the Companys common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to June 30, 2016 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above. |
Summary of Significant Accoun18
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Jun. 30, 2016 | |
Accounting Policies [Abstract] | |
Nature of Business | On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (Rich or the Company). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series A Preferred Stock. Our Series A Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the Assignment Agreement) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled Phorbol esters as anti-neoplastic and white blood cell elevating agents and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series A Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the Sale Agreement) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. |
Cash and Cash Equivalents | The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At June 30, 2016 and March 31, 2016 the Company had $0 and $0, respectively, of unrestricted cash. |
Basis of Presentation | The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission. |
Property and Equipment | Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. |
Long-Lived and Intangible Assets | On July 18, 2013, the Company entered into an Asset Assignment Agreement (the Assignment Agreement) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled Phorbol esters as anti-neoplastic and white blood cell elevating agents and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series A Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the Assignment Agreement) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled Compositions and methods of use of Phorbol Esters for the treatment of Hodgkins Lymphoma, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. |
Fair Value of Financial Instruments | The Companys financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companys assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 Observable inputs such as quoted prices in active markets; Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at June 30, 2016 or March 31, 2015. As of June 30, 2016, the derivative liabilities were considered a level 2 item; see Note 8. |
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. |
Income Taxes | Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. |
Revenue Recognition | The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. |
Research and Development | The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. |
Stock-Based Compensation | Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share. |
Basic loss per share | The basic earnings (loss) per share is calculated by dividing the Companys net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Companys net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. |
Recent Accounting Pronouncements | The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Companys results of operations, financial position or cash flow. |
Property and equipment (Tables)
Property and equipment (Tables) | 3 Months Ended |
Jun. 30, 2016 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment | June 30, 2016 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (1,860 ) (1,429 ) Property and equipment, net $ 3,300 $ 3,731 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 3 Months Ended |
Jun. 30, 2016 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses | June 30, 2016 March 31, 2016 Wages and taxes $ 608,468 $ 514,713 Accrued interest 19,502 15,437 Total accrued expenses $ 627,970 $ 530,150 |
Equity Transactions (Tables)
Equity Transactions (Tables) | 3 Months Ended |
Jun. 30, 2016 | |
Accounting Policies [Abstract] | |
Schedule of Value of Warrants | Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 2,500 2,500 833 Stock price on grant date $30.00 $2.00 $2.00 Exercise price $50.00 $50.00 $50.00 Expected life 1 year 1 year 1 year Volatility 147% 64% 65% Risk-free rate 0.12% 0.11% 0.13% Calculated value $10,473 $0 $0 Fair value allocation of proceeds $7,381 $0 $0 Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 June 9, 2015 Dec 15,2015 Warrants 833 10,000 7,000 7,000 900,000 4,000,000 Stock price on grant date $19.90 $25.20 $3.70 $3.70 $0.02 $0.01 Exercise price $50.00 $35.00 $15.00 $15.00 $0.02 $0.01 Expected life 1 year 3 year 3 year 3 year 5 year 5 year Volatility 113% 76% 119% 119% 98% 98% Risk-free rate 0.12% 0.84% 0.96% 0.98% 1.74% 1.71% Calculated value $3,181 $104,416 $12,130 $12,102 $13,259 $29,612 Fair value allocation of proceeds $2,822 $73,653 $8,637 $8,992 $13,259 $29,612 |
Schedule of Warrant Activity | Number of warrants Weighted average exercise price Outstanding, March 31, 2014 5,833 $50.00 Granted 24,833 $24.00 Exercised - - Outstanding, March 31, 2015 30,666 $29.00 Granted 4,900,000 $0.012 Exercised - - Outstanding, June 30, 2016 4,930,666 $0.192 |
Schedule of Conversions of Common Stock | Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $ 12,000 5,505 $ 2.18 October 1, 2014 $ 12,000 6,487 $ 1.85 October 8, 2014 $ 9,000 5,056 $ 1.78 October 16, 2014 $ 6,000 4,546 $ 1.32 October 29, 2014 $ 15,000 12,500 $ 1.20 November 3, 2014 $ 10,000 8,197 $ 1.22 November 7, 2014 $ 12,000 11,881 $ 1.01 November 19, 2014 $ 18,120 28,312 $ 0.64 December 8, 2014 $ 15,000 34,884 $ 0.43 December 15, 2014 $ 12,000 42,857 $ 0.28 December 26, 2014 $ 17,200 74,783 $ 0.23 February 11, 2015 $ 29,900 747,500 $ 0.04 February 12, 2015 $ 17,333 373,561 $ 0.046 February 13, 2015 $ 17,894 372,800 $ 0.048 February 15, 2015 $ 35,730 739,243 $ 0.048 February 17, 2015 $ 17,003 366,440 $ 0.046 February 23, 2015 $ 20,603 470,900 $ 0.044 February 23, 2015 $ 17,003 366,440 $ 0.046 February 24, 2015 $ 9,488 204,473 $ 0.046 February 26, 2015 $ 42,030 1,050,750 $ 0.040 February 27, 2015 $ 26,880 560,000 $ 0.048 March 2, 2015 $ 56,402 1,215,551 $ 0.046 March 9, 2015 $ 33,900 475,182 $ 0.071 March 10, 2015 $ 25,200 700,000 $ 0.036 March 20, 2015 $ 10,000 181,818 $ 0.006 March 31, 2015 Total $ 498,686 8,059,666 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $ 16,650 411,111 $ 0.04050 April 6, 2015 $ 10,000 209,644 $ 0.04770 April 8, 2015 $ 15,309 453,561 $ 0.03375 April 8, 2015 $ 20,001 454,545 $ 0.04400 April 9, 2015 $ 14,320 325,455 $ 0.04400 April 14, 2015 $ 10,000 236,967 $ 0.04220 April 16, 2015 $ 1,918 53,000 $ 0.03619 April 21, 2015 $ 10,000 259,740 $ 0.03850 April 29, 2015 $ 15,000 389,610 $ 0.03850 May 4, 2015 $ 5,083 131,464 $ 0.03866 May 12, 2015 $ 28,456 903,380 $ 0.03150 May 20, 2015 $ 20,199 947,645 $ 0.02131 May 20, 015 $ 17,240 783,636 $ 0.02200 May 27, 2015 $ 13,568 701,801 $ 0.01933 May 29, 2015 $ 15,000 882,353 $ 0.01700 June 11, 2015 $ 9,897 942,609 $ 0.01050 June 16, 2015 $ 14,100 1,175,000 $ 0.01200 June 16, 2015 $ 13,565 1,130,417 $ 0.01200 June 22, 2015 $ 7,415 1,235,833 $ 0.00600 June 22, 2015 $ 14,384 2,479,924 $ 0.00580 June 23, 2015 $ 7,752 1,292,000 $ 0.00600 September 16, 2015 $ 7,974 1,772,033 $ 0.00450 September 28, 2015 $ 10,000 1,666,667 $ 0.00600 September 29, 2015 $ 10,620 1,770,000 $ 0.00600 October 7, 2015 $ 2,250 375,000 $ 0.00600 October 7, 2015 $ 8,400 1,400,000 $ 0.00600 October 19, 2015 $ 9,720 1,620,000 $ 0.00600 November 2, 2015 $ 4,424 1,966,124 $ 0.00225 November 23, 2015 $ 10,000 1,666,667 $ 0.00600 November 30, 2015 $ 16,844 2,591,323 $ 0.00650 December 9, 2015 $ 1,746 775,991 $ 0.00225 December 17, 2015 $ 5,332 919,319 $ 0.00580 December 28, 2015 $ 1,341 596,200 $ 0.00225 December 28, 2015 $ 17,700 2,950,000 $ 0.00600 December 28, 2015 $ 14,305 2,384,167 $ 0.00600 December 28, 2015 $ 14,963 2,579,916 $ 0.00580 December 29, 2015 $ 8,395 1,399,167 $ 0.00600 December 29, 2015 $ 7,670 1,278,333 $ 0.00600 December 30, 2015 $ 6,651 2,956,248 $ 0.00225 January 1, 2016 $ 28,500 4,384,615 $ 0.00650 January 4, 2016 $ 19,339 3,223,213 $ 0.00600 January 5, 2016 $ 8,107 3,603,227 $ 0.00225 January 6, 2016 $ 16,070 2,678,333 $ 0.00600 January 6, 2016 $ 16,597 2,861,607 $ 0.00580 February 16 ,2016 $ 1,424 4,220,400 $ 0.00034 February 17, 2016 $ 12,800 8,443,272 $ 0.00152 February 23, 2016 $ 4,640 4,218,182 $ 0.00110 February 23, 2016 $ 3,086 4,200,871 $ 0.00073 February 24, 2016 $ 1,492 4,419,970 $ 0.00034 February 25, 2016 $ 3,000 2,638,987 $ 0.00114 February 25, 2016 $ 4,640 4,218,182 $ 0.00110 March 1, 2016 $ 1,313 5,834,458 $ 0.00022 March 2, 2016 $ 4,600 5,831,643 $ 0.00079 March 2, 2016 $ 1,650 2,586,410 $ 0.00064 March 2, 2016 $ 9,332 11,650,000 $ 0.00080 March 7, 2016 $ 2,799 6,546,292 $ 0.00043 March 11, 2016 $ 1,924 4,147,500 $ 0.00046 March 14, 2016 $ 2,245 7,125,777 $ 0.00032 March 15, 2016 $ 3,329 7,454,098 $ 0.00045 March 15, 2016 $ 5,210 11,450,000 $ 0.00046 March 22, 2016 $ 2,419 8,957,888 $ 0.00027 March 22, 2016 $ 2,367 7,200,486 $ 0.00033 March 22, 2016 $ 5,315 11,682,000 $ 0.00046 March 28, 2016 $ 1,986 8,958,779 $ 0.00022 March 31, 2016 Total $ 602,376 194,603,040 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $ 2,197 9,766,311 $ 0.000225 April 4, 2016 $ 4,847 17,250,000 $ 0.000281 April 7, 2016 $ 1,750 9,722,222 $ 0.000180 April 14, 2016 $ 4,158 19,250,000 $ 0.000216 April 15, 2016 $ 1,318 9,766,222 $ 0.000135 April 26, 2016 $ 1,705 12,629,776 $ 0.000135 May 4, 2016 $ 2,067 9,718,025 $ 0.000213 May 31, 2016 $ 828 4,600,055 $ 0.000180 June 2, 2016 $ 9,120 30,000,000 $ 0.000304 June 2, 2016 $ 4,401 29,340,333 $ 0.000150 June 14, 2016 $ 5,847 29,235,900 $ .0.000200 June 17,2016 $ 5,691 28,456,150 $ 0.000200 June 29, 2016 $ 6,580 21,270,355 $ 0.000309 June 30, 2016 Total $ 50,509 231,005,349 |
Schedule of Value of Options | Date May 7, 2014 July 23, 2014 October 6, 2014 April 6, 2015 June 9, 2015 December 15, 2015 Options 35,000 7,500 155,000 2,040,003 1,000,000 860,000 Stock price grant date $12.00 $6.90 $3.58 $0.08 $0.02 $0.01 Initial Exercise price $12.00 $6.90 $1.91984 $0.08 $0.02 $0.01 Modified Exercise price $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 Expected life 10.00 10.00 5.0 5.0 5.0 5.0 Volatility 73% 88% 101% 99% 99% 84% Risk-free rate 2.56% 2.53% 1.04% 1.31% 1.74% 1.70% Calculated value $315,772 $45,109 $454,798 $120,778 $14,838 $5,736 Modified value $7,164 $1,537 $31,408 $151,221 $16,347 $5,736 |
Schedule of Option Activity | Number of options Weighted average exercise price Outstanding, March 31, 2014 475,033 $0.01 Granted 197,500 $0.01 Exercised - - Expired - - Outstanding, March 31, 2015 672,533 $0.01 Granted 3,900,003 $0.01 Exercised - - Expired - - Outstanding, June 30, 2016 4,572,536 $0.01 |
Summary of Significant Accoun22
Summary of Significant Accounting Policies (Details Narrative) | 3 Months Ended | 12 Months Ended | |||||||
Jun. 30, 2016USD ($)$ / sharesshares | Jun. 30, 2015shares | Mar. 31, 2016USD ($)$ / sharesshares | Mar. 31, 2015shares | Mar. 31, 2014shares | Sep. 30, 2013 | Mar. 31, 2013 | Sep. 06, 2013$ / sharesshares | Sep. 05, 2013$ / sharesshares | |
Date Of Incorporation | Aug. 9, 2010 | ||||||||
Common Stock, shares issued | 14,690 | ||||||||
Cancellation of loans | $ | |||||||||
Common Stock, Shares Authorized | 4,000,000,000 | 4,000,000,000 | 375,030,000 | 900,000 | |||||
Common Stock, Par Value | $ / shares | $ .001 | $ .001 | $ 0.001 | $ 0.001 | |||||
Stock split ratio | 4.167 | 4.1671 | |||||||
Cash and cash equivalent | $ | |||||||||
Intangible assets | $ | 0 | ||||||||
Impairment of intangible asset | $ | $ 82,120 | ||||||||
Reserved common shares | 3,900,048 | ||||||||
Stock options granted | 3,900,003 | 197,500 | |||||||
Computer equipment | 3 years | ||||||||
Options granted, number of shares | 3,900,003 | 3,900,003 | 197,500 | 475,033 | |||||
Options, exercise price | $ / shares | $ 0.001 | ||||||||
Sale Agmt | |||||||||
Date of Agreement | Jul. 19, 2013 | ||||||||
Cancellation of loans | $ | $ 28,818 | ||||||||
Shares sold by former officers | 5,312,925 | ||||||||
Shares returned to treasury | 5,002,554 | ||||||||
Shares agreed to cancel | 2,625,210 | ||||||||
Asset Assign Agmt | |||||||||
Date of Agreement | Jul. 18, 2013 | ||||||||
Common Stock, shares issued | 827,670 | ||||||||
Series A Preferred Stock, shares issued | 6,000,000 | ||||||||
Stock Value | $ | $ 123,973 | ||||||||
Termination of agreement | $ | 20,000 | ||||||||
Additional cash required | $ | $ 2,000,000 |
Property and equipment - Schedu
Property and equipment - Schedule of Property and Equipment (Details) - USD ($) | Jun. 30, 2016 | Mar. 31, 2016 |
Property, Plant and Equipment [Abstract] | ||
Computer equipment | $ 5,160 | $ 5,160 |
Less: accumulated depreciation | (1,860) | (1,429) |
Property and equipment, net | $ 3,300 | $ 3,731 |
Property and Equipment (Details
Property and Equipment (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | Mar. 31, 2016 | |
Property And Equipment Details Narrative | |||
Depreciation expense | $ 431 | $ 118 | $ 799 |
Computer equipment | 3 years |
Intangible Assets (Details Narr
Intangible Assets (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended |
Jun. 30, 2016 | Mar. 31, 2016 | |
Common Stock, shares issued | 14,690 | |
Impairment of intangible asset | $ 82,120 | |
Asset Assign Agmt | ||
Date of Agreement | Jul. 18, 2013 | |
Common Stock, shares issued | 827,670 | |
Series A Preferred Stock, shares issued | 6,000,000 | |
Stock Value | $ 123,973 | |
Asset Assign Agmt #2 | ||
Date of Agreement | Oct. 6, 2014 | |
Common Stock, shares issued | 2,207,920 | |
Common stock, value | $ 7,904,355 | |
Impaired Assets | 0 | |
Impairment of intangible asset | $ 82,120 |
Accrued Expenses - Schedule of
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) | Jun. 30, 2016 | Mar. 31, 2016 |
Payables and Accruals [Abstract] | ||
Wages and taxes | $ 608,468 | $ 514,713 |
Accrued interest | 19,502 | 15,437 |
Total accrued expenses | $ 627,970 | $ 530,150 |
Related Party Debt and Transa27
Related Party Debt and Transactions (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |||
Jun. 30, 2016 | Jun. 30, 2015 | Mar. 31, 2015 | Mar. 31, 2014 | Mar. 31, 2016 | |
Cancellation of loans | |||||
Due to related parties | 39,138 | $ 76,913 | |||
Loans and interest received (repaid) from/to related parties | (37,775) | ||||
Interest expense, related party | (75) | $ (74) | |||
Accrued expenses | $ 627,970 | 530,150 | |||
Sale Agmt | |||||
Date of Agreement | Jul. 19, 2013 | ||||
Cancellation of loans | $ 28,818 | ||||
CEO | |||||
Loan from related party | $ 5,000 | $ 36,000 | |||
Repayment of loans to related parties | 41,000 | ||||
SH Loan #1 | |||||
Loan from related party | $ 6,000 | ||||
Interest Rate | 8.00% | ||||
Interest expense, related party | $ (367) | ||||
SH Loan #2 | |||||
Loan from related party | $ 6,280 | ||||
Interest Rate | 8.00% | ||||
Interest expense, related party | $ (442) | ||||
Employment Agmt | |||||
Date of Agreement | Sep. 6, 2013 | ||||
Term of Agreement | 2 years | ||||
Annual Compensation | $ 275,000 | ||||
Options to purchase | 30,002 | ||||
Options to purchase, exercise price | $ 0.02 | ||||
Bonus | $ 68,750 | ||||
Earnings | 68,749 | 275,000 | |||
Accrued Earnings | 462,612 | $ 395,630 | |||
Related Party Loans | |||||
Repayment of loans to related parties | 24,009 | ||||
Accrued expenses | 3,100 | $ 22,200 | |||
Accrued expenses, balance due | $ 1,291 |
Stock Deposits (Details Narrati
Stock Deposits (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2016 | Mar. 31, 2016 | Mar. 31, 2014 | |
Notes to Financial Statements | |||
Stock deposits reclassified as common stock and stock warrants | $ 147,050 | ||
Stock issued in exchange for deposits | 14,690 |
Convertible Note Payable (Detai
Convertible Note Payable (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Mar. 31, 2016 | Mar. 31, 2015 | |
Debt Instrument, Converted Amount | $ 50,510 | $ 449,825 | ||
Debt Instrument, Interest Accrued, Converted Amount | 3,449 | |||
Common Stock, shares issued | 14,690 | |||
Convertible Prom Note #1 | ||||
Date of Agreement | Mar. 11, 2014 | |||
Convertible Note | $ 37,500 | |||
Interest Rate | 8.00% | |||
Due Date | Dec. 13, 2014 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 37,500 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,500 | |||
Common Stock, shares issued | 21,593 | |||
Convertible Prom Note #2 | ||||
Date of Agreement | Apr. 8, 2014 | |||
Convertible Note | $ 53,000 | |||
Interest Rate | 8.00% | |||
Due Date | Jan. 14, 2015 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 53,000 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,120 | |||
Common Stock, shares issued | 60,890 | |||
Convertible Prom Note #3 | ||||
Date of Agreement | May 21, 2014 | |||
Convertible Note | $ 42,500 | |||
Interest Rate | 8.00% | |||
Due Date | Feb. 23, 2015 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 42,500 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,700 | |||
Common Stock, shares issued | 152,524 | |||
Convertible Prom Note #4 | ||||
Date of Agreement | Aug. 14, 2014 | |||
Convertible Note | $ 66,780 | |||
Interest Rate | 8.00% | |||
Due Date | Aug. 14, 2015 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Original Issue Discount | 3,380 | |||
Debt Instrument, Converted Amount | 66,780 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,850 | |||
Common Stock, shares issued | 1,214,425 | |||
Convertible Prom Note #5 | ||||
Date of Agreement | Aug. 14, 2014 | |||
Convertible Note | $ 58,300 | |||
Interest Rate | 8.00% | |||
Due Date | Aug. 14, 2015 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Original Issue Discount | 3,300 | |||
Debt Instrument, Converted Amount | 58,300 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,527 | |||
Common Stock, shares issued | 1,310,912 | |||
Convertible Prom Note #6 | ||||
Date of Agreement | Aug. 13, 2014 | |||
Convertible Note | $ 61,111 | |||
Interest Rate | 12.00% | |||
Due Date | Aug. 14, 2016 | |||
Interest Accrued | 0 | $ 1,067 | ||
Convertible Note, Balance | 0 | |||
Original Issue Discount | 5,500 | |||
Debt Instrument, Converted Amount | 61,111 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,067 | $ 6,266 | ||
Common Stock, shares issued | 177,836 | 1,403,700 | ||
Convertible Prom Note #7 | ||||
Date of Agreement | Aug. 19, 2014 | |||
Convertible Note | $ 57,895 | |||
Interest Rate | 12.00% | |||
Due Date | Aug. 19, 2016 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Original Issue Discount | 2,895 | |||
Debt Instrument, Converted Amount | 57,895 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 14,035 | |||
Common Stock, shares issued | 1,798,250 | |||
Convertible Prom Note #8 | ||||
Date of Agreement | Sep. 18, 2014 | |||
Convertible Note | $ 64,500 | |||
Interest Rate | 12.00% | |||
Due Date | Sep. 18, 2015 | |||
Interest Accrued | $ 0 | $ 8,240 | ||
Convertible Note, Balance | 0 | 54,500 | ||
Original Issue Discount | 5,500 | |||
Debt Instrument, Converted Amount | 54,500 | $ 10,000 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 8,240 | |||
Common Stock, shares issued | 1,879,597 | 181,819 | ||
Convertible Prom Note #9 | ||||
Date of Agreement | Sep. 23, 2014 | |||
Convertible Note | $ 55,000 | |||
Interest Rate | 8.00% | |||
Due Date | Jun. 23, 2015 | |||
Interest Accrued | $ 0 | $ 2,158 | ||
Convertible Note, Balance | 0 | 29,800 | ||
Debt Instrument, Converted Amount | 29,800 | $ 25,200 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,158 | |||
Common Stock, shares issued | 864,672 | 700,000 | ||
Convertible Prom Note #10 | ||||
Date of Agreement | Oct. 6, 2014 | |||
Convertible Note | $ 33,000 | |||
Interest Rate | 8.00% | |||
Due Date | Jul. 6, 2015 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 33,000 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,320 | |||
Common Stock, shares issued | 780,000 | |||
Convertible Prom Note #11 | ||||
Date of Agreement | Nov. 6, 2014 | |||
Convertible Note | $ 55,000 | |||
Interest Rate | 12.00% | |||
Due Date | May 6, 2015 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 55,000 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 3,553 | |||
Common Stock, shares issued | 2,813,634 | |||
Convertible Prom Note #12 | ||||
Date of Agreement | Nov. 25, 2014 | |||
Convertible Note | $ 43,000 | |||
Interest Rate | 8.00% | |||
Due Date | Aug. 28, 2015 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | $ 46,510 | |||
Common Stock, shares issued | 5,290,270 | |||
Fee | Default | |||
Fee Amount | $ 3,510 | |||
Convertible Prom Note #13 | ||||
Date of Agreement | Dec. 16, 2014 | |||
Convertible Note | $ 33,333 | |||
Interest Rate | 12.00% | |||
Due Date | Dec. 16, 2016 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Original Issue Discount | 3,333 | |||
Debt Instrument, Converted Amount | 33,333 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 4,000 | |||
Common Stock, shares issued | 5,047,167 | |||
Convertible Prom Note #14 | ||||
Date of Agreement | Jan. 9, 2015 | |||
Convertible Note | $ 33,000 | |||
Interest Rate | 8.00% | |||
Due Date | Oct. 13, 2015 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,320 | |||
Common Stock, shares issued | 8,470,000 | |||
Fee | Default | |||
Fee Amount | $ 16,500 | |||
Convertible Prom Note #15 | ||||
Date of Agreement | Feb. 5, 2015 | |||
Convertible Note | $ 54,000 | |||
Interest Rate | 8.00% | |||
Due Date | Nov. 9, 2015 | |||
Interest Accrued | $ 5,156 | |||
Convertible Note, Balance | $ 47,980 | |||
Common Stock, shares issued | 12,393,030 | |||
Fee | Default | |||
Fee Amount | $ 27,000 | |||
Convertible Prom Note #16 | ||||
Date of Agreement | Feb. 17, 2015 | |||
Convertible Note | $ 66,780 | |||
Interest Rate | 8.00% | |||
Due Date | Aug. 14, 2015 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Original Issue Discount | 6,780 | |||
Debt Instrument, Converted Amount | 66,780 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 3,148 | |||
Common Stock, shares issued | 8,854,031 | |||
Convertible Prom Note #17 | ||||
Date of Agreement | Feb. 25, 2015 | |||
Convertible Note | $ 27,778 | |||
Interest Rate | 12.00% | |||
Due Date | Feb. 25, 2017 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 27,778 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 3,333 | |||
Common Stock, shares issued | 5,185,210 | |||
Convertible Prom Note #18 | ||||
Date of Agreement | Mar. 9, 2015 | |||
Convertible Note | $ 55,000 | |||
Interest Rate | 8.00% | |||
Due Date | Jun. 23, 2017 | Dec. 9, 2015 | ||
Interest Accrued | $ 0 | $ 0 | ||
Convertible Note, Balance | 8,838 | 16,215 | ||
Debt Instrument, Converted Amount | 7,377 | 38,785 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 422 | $ 5,135 | ||
Common Stock, shares issued | 46,484,586 | 57,733,852 | ||
Convertible Prom Note #19 | ||||
Date of Agreement | Mar. 26, 2015 | |||
Convertible Note | $ 29,680 | |||
Interest Rate | 8.00% | |||
Due Date | Mar. 23, 2016 | |||
Interest Accrued | $ 3,543 | $ 2,577 | ||
Convertible Note, Balance | 18,751 | |||
Original Issue Discount | 1,680 | |||
Debt Instrument, Converted Amount | $ 10,929 | |||
Common Stock, shares issued | 15,924,728 | |||
Convertible Prom Note #20 | ||||
Date of Agreement | Mar. 2, 2015 | |||
Convertible Note | $ 58,300 | |||
Interest Rate | 8.00% | |||
Due Date | Aug. 14, 2015 | |||
Interest Accrued | 0 | |||
Convertible Note, Balance | 0 | $ 1,898 | ||
Original Issue Discount | 3,300 | |||
Debt Instrument, Converted Amount | 1,898 | $ 56,402 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 20 | |||
Common Stock, shares issued | 53,000 | 1,215,551 | ||
Convertible Prom Note #21 | ||||
Date of Agreement | May 5, 2015 | |||
Convertible Note | $ 68,900 | |||
Interest Rate | 8.00% | |||
Due Date | May 5, 2016 | |||
Interest Accrued | $ 4,860 | $ 4,387 | ||
Convertible Note, Balance | 52,500 | 60,439 | ||
Original Issue Discount | 3,900 | |||
Original Issue Discount, unamortized | 325 | |||
Debt Instrument, Converted Amount | 7,939 | 8,461 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 707 | $ 566 | ||
Common Stock, shares issued | 30,988,380 | 18,135,267 | ||
Convertible Prom Note #22 | ||||
Date of Agreement | May 6, 2015 | |||
Convertible Note | $ 10,500 | |||
Interest Rate | 8.00% | |||
Due Date | Feb. 8, 2016 | |||
Interest Accrued | $ 1,133 | |||
Convertible Note, Balance | $ 15,750 | |||
Fee | Default | |||
Fee Amount | $ 5,250 | |||
Convertible Prom Note #23 | ||||
Date of Agreement | May 27, 2015 | |||
Convertible Note | $ 16,500 | |||
Interest Rate | 8.00% | |||
Due Date | May 28, 2016 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 16,500 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 344 | |||
Common Stock, shares issued | 2,591,323 | |||
Convertible Prom Note #24 | ||||
Date of Agreement | Aug. 28, 2015 | |||
Convertible Note | $ 15,000 | |||
Interest Rate | 8.00% | |||
Due Date | Aug. 28, 2016 | |||
Interest Accrued | $ 0 | |||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 15,000 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 939 | |||
Common Stock, shares issued | 87,032,383 | |||
Convertible Prom Note #25 | ||||
Date of Agreement | Sep. 4, 2015 | |||
Convertible Note | $ 19,000 | |||
Interest Rate | 8.00% | |||
Due Date | Jun. 4, 2016 | |||
Interest Accrued | $ 1,249 | |||
Convertible Note, Balance | $ 19,000 | |||
Convertible Prom Note #26 | ||||
Date of Agreement | Dec. 29, 2015 | |||
Convertible Note | $ 57,378 | |||
Interest Rate | 8.00% | |||
Due Date | Jun. 23, 2017 | Dec. 30, 2016 | ||
Interest Accrued | $ 18 | $ 0 | ||
Convertible Note, Balance | 1,609 | |||
Debt Instrument, Converted Amount | 59,934 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,222 | |||
Common Stock, shares issued | 35,927,887 | |||
Fee | Default | |||
Fee Amount | $ 4,165 | |||
Convertible Prom Note #27 | ||||
Date of Agreement | Jan. 22, 2016 | |||
Convertible Note | $ 60,500 | |||
Interest Rate | 10.00% | |||
Due Date | Oct. 22, 2016 | |||
Interest Accrued | $ 2,652 | |||
Convertible Prom Note #28 | ||||
Date of Agreement | Feb. 25, 2016 | |||
Convertible Note | $ 27,500 | |||
Interest Rate | 8.00% | |||
Due Date | Feb. 25, 2017 | |||
Interest Accrued | 0 | $ 191 | ||
Convertible Note, Balance | 10,755 | 27,500 | ||
Original Issue Discount, unamortized | 1,460 | |||
Debt Instrument, Converted Amount | 16,745 | $ 5,315 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,380 | |||
Common Stock, shares issued | 66,500,000 | 11,682,000 | ||
Convertible Prom Note #29 | ||||
Date of Agreement | Mar. 24, 2016 | |||
Convertible Note | $ 7,500 | |||
Interest Rate | 8.00% | |||
Due Date | Mar. 24, 2017 | |||
Interest Accrued | $ 161 | |||
Convertible Prom Note #34 | ||||
Date of Agreement | May 25, 2016 | |||
Convertible Note | $ 30,000 | |||
Interest Rate | 8.00% | |||
Due Date | May 25, 2017 | |||
Interest Accrued | $ 237 | |||
Convertible Prom Note #30 | ||||
Date of Agreement | Jun. 8, 2016 | |||
Convertible Note | $ 84,250 | |||
Interest Rate | 8.00% | |||
Due Date | Jun. 8, 2017 | |||
Interest Accrued | $ 406 | |||
Convertible Prom Note #32 | ||||
Date of Agreement | Jun. 23, 2016 | |||
Convertible Note | $ 56,000 | |||
Interest Rate | 8.00% | |||
Due Date | Jun. 23, 2017 | |||
Interest Accrued | $ 86 |
Derivative Liabilities (Details
Derivative Liabilities (Details Narrative) - USD ($) | 3 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Mar. 31, 2016 | |
Notes to Financial Statements | |||
Change in value of derivative liability | $ (116,771) | $ (48,413) | |
Derivative expense | $ (191,844) | ||
Debt Discount, Unamortized | 41,792 | ||
Derivative liabilities | 322,214 | $ 446,912 | |
Derivative liabilities |
Equity Transactions - Schedule
Equity Transactions - Schedule of Value of Warrants (Details) - USD ($) | 3 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | |
Fair value allocation of proceeds | $ 13,259 | |
Warrant #1 | ||
Date | Oct. 29, 2013 | |
Warrants | $ 2,500 | |
Stock price on grant date | $ 30 | |
Exercise price | $ 50 | |
Expected life | 1 year | |
Volatility | 147.00% | |
Risk-free rate | 0.12% | |
Calculated value | $ 10,473 | |
Fair value allocation of proceeds | $ 7,381 | |
Warrant #2 | ||
Date | Dec. 11, 2013 | |
Warrants | $ 2,500 | |
Stock price on grant date | $ 2 | |
Exercise price | $ 50 | |
Expected life | 1 year | |
Volatility | 64.00% | |
Risk-free rate | 0.11% | |
Calculated value | $ 0 | |
Fair value allocation of proceeds | $ 0 | |
Warrant #3 | ||
Date | Mar. 10, 2014 | |
Warrants | $ 833 | |
Stock price on grant date | $ 2 | |
Exercise price | $ 50 | |
Expected life | 1 year | |
Volatility | 65.00% | |
Risk-free rate | 0.13% | |
Calculated value | $ 0 | |
Fair value allocation of proceeds | $ 0 | |
Warrant #4 | ||
Date | Apr. 4, 2014 | |
Warrants | $ 833 | |
Stock price on grant date | $ 19.90 | |
Exercise price | $ 50 | |
Expected life | 1 year | |
Volatility | 113.00% | |
Risk-free rate | 0.12% | |
Calculated value | $ 3,181 | |
Fair value allocation of proceeds | $ 2,822 | |
Warrant #5 | ||
Date | Apr. 24, 2014 | |
Warrants | $ 10,000 | |
Stock price on grant date | $ 25.20 | |
Exercise price | $ 35 | |
Expected life | 3 years | |
Volatility | 76.00% | |
Risk-free rate | 0.84% | |
Calculated value | $ 104,416 | |
Fair value allocation of proceeds | $ 73,653 | |
Warrant #6 | ||
Date | Jul. 10, 2014 | |
Warrants | $ 7,000 | |
Stock price on grant date | $ 3.70 | |
Exercise price | $ 15 | |
Expected life | 3 years | |
Volatility | 119.00% | |
Risk-free rate | 0.96% | |
Calculated value | $ 12,130 | |
Fair value allocation of proceeds | $ 8,637 | |
Warrant #7 | ||
Date | Jul. 29, 2014 | |
Warrants | $ 7,000 | |
Stock price on grant date | $ 3.70 | |
Exercise price | $ 15 | |
Expected life | 3 years | |
Volatility | 119.00% | |
Risk-free rate | 0.98% | |
Calculated value | $ 12,102 | |
Fair value allocation of proceeds | $ 8,992 | |
Warrant #8 | ||
Date | Jun. 9, 2015 | |
Warrants | $ 900,000 | |
Stock price on grant date | $ 0.02 | |
Exercise price | $ 0.02 | |
Expected life | 5 years | |
Volatility | 98.00% | |
Risk-free rate | 1.74% | |
Calculated value | $ 13,259 | |
Fair value allocation of proceeds | $ 13,259 | |
Warrant #9 | ||
Date | Dec. 15, 2015 | |
Warrants | $ 4,000,000 | |
Stock price on grant date | $ 0.01 | |
Exercise price | $ 0.01 | |
Expected life | 5 years | |
Volatility | 98.00% | |
Risk-free rate | 1.71% | |
Calculated value | $ 29,612 | |
Fair value allocation of proceeds | $ 29,612 |
Equity Transactions - Schedul32
Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares | 12 Months Ended | ||
Mar. 31, 2016 | Mar. 31, 2015 | Mar. 31, 2014 | |
Accounting Policies [Abstract] | |||
Beginning Balance, Issued Warrants | 30,666 | 5,833 | |
Beginning Balance, Average Exercise Price | $ 29 | $ 50 | |
Issued, Warrants | 4,900,000 | 24,833 | 5,833 |
Issued, Average Exercise Price | $ 0.012 | $ 24 | $ 50 |
Exercised, Warrants | |||
Exercised, Average Exercise Price | |||
Expired Warrants | |||
Expired Average Exercise Price | |||
Ending Balance, Issued Warrants | 4,930,666 | 30,666 | 5,833 |
Ending Balance, Average Exercise Price | $ 0.192 | $ 29 | $ 50 |
Equity Transactions - Schedul33
Equity Transactions - Schedule of Value of Options (Details) | 3 Months Ended |
Jun. 30, 2016USD ($)$ / sharesshares | |
Stock Option 4 | |
Date of Issuance | May 7, 2014 |
Options | shares | 35,000 |
Stock price on grant date | $ 12 |
Exercise price | 12 |
Exercise price, modified | $ 0.01 |
Expected life | 10 years |
Volatility | 73.00% |
Risk-free rate | 2.56% |
Calculated value | $ | $ 315,772 |
Modified value | $ | $ 7,164 |
Stock Option 5 | |
Date of Issuance | Jul. 23, 2014 |
Options | shares | 7,500 |
Stock price on grant date | $ 6.90 |
Exercise price | 6.90 |
Exercise price, modified | $ 0.01 |
Expected life | 10 years |
Volatility | 88.00% |
Risk-free rate | 2.53% |
Calculated value | $ | $ 45,109 |
Modified value | $ | $ 1,537 |
Stock Option 6 | |
Date of Issuance | Oct. 6, 2014 |
Options | shares | 155,000 |
Stock price on grant date | $ 3.58 |
Exercise price | 1.91984 |
Exercise price, modified | $ 0.01 |
Expected life | 5 years |
Volatility | 101.00% |
Risk-free rate | 1.04% |
Calculated value | $ | $ 454,798 |
Modified value | $ | $ 31,408 |
Stock Option 7 | |
Date of Issuance | Apr. 6, 2015 |
Options | shares | 2,040,003 |
Stock price on grant date | $ 0.08 |
Exercise price | 0.08 |
Exercise price, modified | $ 0.01 |
Expected life | 5 years |
Volatility | 99.00% |
Risk-free rate | 1.31% |
Calculated value | $ | $ 120,778 |
Modified value | $ | $ 151,221 |
Stock Option 8 | |
Date of Issuance | Jun. 9, 2015 |
Options | shares | 1,000,000 |
Stock price on grant date | $ 0.02 |
Exercise price | 0.02 |
Exercise price, modified | $ 0.01 |
Expected life | 5 years |
Volatility | 99.00% |
Risk-free rate | 1.74% |
Calculated value | $ | $ 14,838 |
Modified value | $ | $ 16,347 |
Stock Option 9 | |
Date of Issuance | Dec. 15, 2015 |
Options | shares | 860,000 |
Stock price on grant date | $ 0.01 |
Exercise price | 0.01 |
Exercise price, modified | $ 0.01 |
Expected life | 5 years |
Volatility | 84.00% |
Risk-free rate | 1.70% |
Calculated value | $ | $ 5,736 |
Modified value | $ | $ 5,736 |
Equity Transactions - Schedul34
Equity Transactions - Schedule of Option Activity (Details) - shares | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2015 | Mar. 31, 2016 | Mar. 31, 2015 | Mar. 31, 2014 | |
Accounting Policies [Abstract] | ||||
Beginning Balance, number of shares | 672,533 | 672,533 | 475,033 | |
Beginning Balance, weighted average exercise price | 0.01 | 0.01 | 0.01 | |
Options granted, number of shares | 3,900,003 | 3,900,003 | 197,500 | 475,033 |
Options granted, weighted average exercise price | 0.01 | 0.01 | 0.01 | |
Options exercised, number of shares | ||||
Options exercised, weighted average exercise price | ||||
Options expired, number of shares | ||||
Options expired, weighted average exercise price | ||||
Ending Balance, number of shares | 4,572,536 | 672,533 | 475,033 | |
Ending Balance, weighted average exercise price | 0.01 | 0.01 | 0.01 |
Equity Transactions (Details Na
Equity Transactions (Details Narrative) | 3 Months Ended | 12 Months Ended | ||||||||
Jun. 30, 2016USD ($)$ / sharesshares | Jun. 30, 2015USD ($)shares | Mar. 31, 2016$ / sharesshares | Mar. 31, 2015shares | Mar. 31, 2014shares | Sep. 30, 2013 | Mar. 31, 2013 | Sep. 06, 2013$ / sharesshares | Sep. 05, 2013$ / sharesshares | Jul. 18, 2013shares | |
Common Stock, Shares Authorized | 4,000,000,000 | 4,000,000,000 | 375,030,000 | 900,000 | ||||||
Common Stock, Par Value | $ / shares | $ .001 | $ .001 | $ 0.001 | $ 0.001 | ||||||
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | ||||||||
Preferred Stock, Par Value | $ / shares | $ .001 | $ .001 | ||||||||
Series A Preferred Stock, Designated | 6,000,000 | |||||||||
Common Stock, Issued | 447,369,610 | 216,364,262 | ||||||||
Preferred Stock, Issued | 6,000,000 | 6,000,000 | ||||||||
Common Stock, shares issued | 14,690 | |||||||||
Stock split ratio | 4.167 | 4.1671 | ||||||||
Options granted, number of shares | 3,900,003 | 3,900,003 | 197,500 | 475,033 | ||||||
Debt Instrument, Converted Amount | $ | $ 50,510 | $ 449,825 | ||||||||
Stock-based compensation | $ | $ 130,091 | |||||||||
Debt Conversion #1 | ||||||||||
Date of Issuance | Sep. 22, 2014 | |||||||||
Common Stock, shares issued | 5,505 | |||||||||
Common Stock, price per share | $ / shares | $ 2.18 | |||||||||
Debt Instrument, Converted Amount | $ | $ 12,000 | |||||||||
Debt Conversion #2 | ||||||||||
Date of Issuance | Oct. 1, 2014 | |||||||||
Common Stock, shares issued | 6,487 | |||||||||
Common Stock, price per share | $ / shares | $ 1.85 | |||||||||
Debt Instrument, Converted Amount | $ | $ 12,000 | |||||||||
Debt Conversion #3 | ||||||||||
Date of Issuance | Oct. 8, 2014 | |||||||||
Common Stock, shares issued | 5,056 | |||||||||
Common Stock, price per share | $ / shares | $ 1.78 | |||||||||
Debt Instrument, Converted Amount | $ | $ 9,000 | |||||||||
Debt Conversion #4 | ||||||||||
Date of Issuance | Oct. 16, 2014 | |||||||||
Common Stock, shares issued | 4,546 | |||||||||
Common Stock, price per share | $ / shares | $ 1.32 | |||||||||
Debt Instrument, Converted Amount | $ | $ 6,000 | |||||||||
Debt Conversion #5 | ||||||||||
Date of Issuance | Oct. 29, 2014 | |||||||||
Common Stock, shares issued | 12,500 | |||||||||
Common Stock, price per share | $ / shares | $ 1.20 | |||||||||
Debt Instrument, Converted Amount | $ | $ 15,000 | |||||||||
Debt Conversion #6 | ||||||||||
Date of Issuance | Nov. 3, 2014 | |||||||||
Common Stock, shares issued | 8,197 | |||||||||
Common Stock, price per share | $ / shares | $ 1.22 | |||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | |||||||||
Debt Conversion #7 | ||||||||||
Date of Issuance | Nov. 7, 2014 | |||||||||
Common Stock, shares issued | 11,881 | |||||||||
Common Stock, price per share | $ / shares | $ 1.01 | |||||||||
Debt Instrument, Converted Amount | $ | $ 12,000 | |||||||||
Debt Conversion #8 | ||||||||||
Date of Issuance | Nov. 19, 2014 | |||||||||
Common Stock, shares issued | 28,312 | |||||||||
Common Stock, price per share | $ / shares | $ 0.64 | |||||||||
Debt Instrument, Converted Amount | $ | $ 18,120 | |||||||||
Debt Conversion #9 | ||||||||||
Date of Issuance | Dec. 8, 2014 | |||||||||
Common Stock, shares issued | 34,884 | |||||||||
Common Stock, price per share | $ / shares | $ 0.43 | |||||||||
Debt Instrument, Converted Amount | $ | $ 15,000 | |||||||||
Debt Conversion #10 | ||||||||||
Date of Issuance | Dec. 15, 2014 | |||||||||
Common Stock, shares issued | 42,857 | |||||||||
Common Stock, price per share | $ / shares | $ 0.28 | |||||||||
Debt Instrument, Converted Amount | $ | $ 12,000 | |||||||||
Debt Conversion #11 | ||||||||||
Date of Issuance | Dec. 26, 2014 | |||||||||
Common Stock, shares issued | 74,783 | |||||||||
Common Stock, price per share | $ / shares | $ 0.23 | |||||||||
Debt Instrument, Converted Amount | $ | $ 17,200 | |||||||||
Debt Conversion #12 | ||||||||||
Date of Issuance | Feb. 11, 2015 | |||||||||
Common Stock, shares issued | 747,500 | |||||||||
Common Stock, price per share | $ / shares | $ 0.04 | |||||||||
Debt Instrument, Converted Amount | $ | $ 29,900 | |||||||||
Debt Conversion #13 | ||||||||||
Date of Issuance | Feb. 12, 2015 | |||||||||
Common Stock, shares issued | 373,561 | |||||||||
Common Stock, price per share | $ / shares | $ 0.046 | |||||||||
Debt Instrument, Converted Amount | $ | $ 17,333 | |||||||||
Debt Conversion #15 | ||||||||||
Date of Issuance | Feb. 13, 2015 | |||||||||
Common Stock, shares issued | 372,800 | |||||||||
Common Stock, price per share | $ / shares | $ 0.048 | |||||||||
Debt Instrument, Converted Amount | $ | $ 17,894 | |||||||||
Debt Conversion #14 | ||||||||||
Date of Issuance | Feb. 15, 2015 | |||||||||
Common Stock, shares issued | 739,243 | |||||||||
Common Stock, price per share | $ / shares | $ 0.048 | |||||||||
Debt Instrument, Converted Amount | $ | $ 35,730 | |||||||||
Debt Conversion #16 | ||||||||||
Date of Issuance | Feb. 17, 2015 | |||||||||
Common Stock, shares issued | 366,440 | |||||||||
Common Stock, price per share | $ / shares | $ 0.046 | |||||||||
Debt Instrument, Converted Amount | $ | $ 17,003 | |||||||||
Debt Conversion #17 | ||||||||||
Date of Issuance | Feb. 23, 2015 | |||||||||
Common Stock, shares issued | 470,900 | |||||||||
Common Stock, price per share | $ / shares | $ 0.044 | |||||||||
Debt Instrument, Converted Amount | $ | $ 20,603 | |||||||||
Debt Conversion #18 | ||||||||||
Date of Issuance | Feb. 23, 2015 | |||||||||
Common Stock, shares issued | 366,440 | |||||||||
Common Stock, price per share | $ / shares | $ 0.046 | |||||||||
Debt Instrument, Converted Amount | $ | $ 17,003 | |||||||||
Debt Conversion #19 | ||||||||||
Date of Issuance | Feb. 24, 2015 | |||||||||
Common Stock, shares issued | 204,473 | |||||||||
Common Stock, price per share | $ / shares | $ 0.046 | |||||||||
Debt Instrument, Converted Amount | $ | $ 9,488 | |||||||||
Debt Conversion #20 | ||||||||||
Date of Issuance | Feb. 26, 2015 | |||||||||
Common Stock, shares issued | 1,050,750 | |||||||||
Common Stock, price per share | $ / shares | $ 0.040 | |||||||||
Debt Instrument, Converted Amount | $ | $ 42,030 | |||||||||
Debt Conversion #21 | ||||||||||
Date of Issuance | Feb. 27, 2015 | |||||||||
Common Stock, shares issued | 560,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.048 | |||||||||
Debt Instrument, Converted Amount | $ | $ 26,880 | |||||||||
Debt Conversion #22 | ||||||||||
Date of Issuance | Mar. 2, 2015 | |||||||||
Common Stock, shares issued | 1,215,551 | |||||||||
Common Stock, price per share | $ / shares | $ 0.046 | |||||||||
Debt Instrument, Converted Amount | $ | $ 56,402 | |||||||||
Debt Conversion #23 | ||||||||||
Date of Issuance | Mar. 9, 2015 | |||||||||
Common Stock, shares issued | 475,182 | |||||||||
Common Stock, price per share | $ / shares | $ 0.071 | |||||||||
Debt Instrument, Converted Amount | $ | $ 33,900 | |||||||||
Debt Conversion #24 | ||||||||||
Date of Issuance | Mar. 10, 2015 | |||||||||
Common Stock, shares issued | 700,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.036 | |||||||||
Debt Instrument, Converted Amount | $ | $ 25,200 | |||||||||
Debt Conversion #25 | ||||||||||
Date of Issuance | Mar. 20, 2015 | |||||||||
Common Stock, shares issued | 181,818 | |||||||||
Common Stock, price per share | $ / shares | $ 0.006 | |||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | |||||||||
Debt Conversion #26 | ||||||||||
Date of Issuance | Apr. 1, 2015 | |||||||||
Common Stock, shares issued | 411,111 | |||||||||
Common Stock, price per share | $ / shares | $ 0.04050 | |||||||||
Debt Instrument, Converted Amount | $ | $ 16,650 | |||||||||
Debt Conversion #27 | ||||||||||
Date of Issuance | Apr. 6, 2015 | |||||||||
Common Stock, shares issued | 209,644 | |||||||||
Common Stock, price per share | $ / shares | $ 0.04770 | |||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | |||||||||
Debt Conversion #28 | ||||||||||
Date of Issuance | Apr. 8, 2015 | |||||||||
Common Stock, shares issued | 453,561 | |||||||||
Common Stock, price per share | $ / shares | $ 0.03375 | |||||||||
Debt Instrument, Converted Amount | $ | $ 15,309 | |||||||||
Debt Conversion #29 | ||||||||||
Date of Issuance | Apr. 9, 2015 | |||||||||
Common Stock, shares issued | 325,455 | |||||||||
Common Stock, price per share | $ / shares | $ 0.04400 | |||||||||
Debt Instrument, Converted Amount | $ | $ 14,320 | |||||||||
Debt Conversion #30 | ||||||||||
Date of Issuance | Apr. 14, 2015 | |||||||||
Common Stock, shares issued | 236,967 | |||||||||
Common Stock, price per share | $ / shares | $ 0.04220 | |||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | |||||||||
Debt Conversion #31 | ||||||||||
Date of Issuance | Apr. 16, 2015 | |||||||||
Common Stock, shares issued | 53,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.03619 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,918 | |||||||||
Debt Conversion #32 | ||||||||||
Date of Issuance | Apr. 21, 2015 | |||||||||
Common Stock, shares issued | 259,740 | |||||||||
Common Stock, price per share | $ / shares | $ 0.03850 | |||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | |||||||||
Debt Conversion #33 | ||||||||||
Date of Issuance | Apr. 29, 2015 | |||||||||
Common Stock, shares issued | 389,610 | |||||||||
Common Stock, price per share | $ / shares | $ 0.03850 | |||||||||
Debt Instrument, Converted Amount | $ | $ 15,000 | |||||||||
Debt Conversion #34 | ||||||||||
Date of Issuance | May 4, 2015 | |||||||||
Common Stock, shares issued | 131,464 | |||||||||
Common Stock, price per share | $ / shares | $ 0.03866 | |||||||||
Debt Instrument, Converted Amount | $ | $ 5,083 | |||||||||
Debt Conversion #35 | ||||||||||
Date of Issuance | May 12, 2015 | |||||||||
Common Stock, shares issued | 903,380 | |||||||||
Common Stock, price per share | $ / shares | $ 0.03150 | |||||||||
Debt Instrument, Converted Amount | $ | $ 28,456 | |||||||||
Debt Conversion #36 | ||||||||||
Date of Issuance | May 20, 2015 | |||||||||
Common Stock, shares issued | 947,645 | |||||||||
Common Stock, price per share | $ / shares | $ 0.02131 | |||||||||
Debt Instrument, Converted Amount | $ | $ 20,199 | |||||||||
Debt Conversion #37 | ||||||||||
Date of Issuance | May 20, 2015 | |||||||||
Common Stock, shares issued | 783,636 | |||||||||
Common Stock, price per share | $ / shares | $ 0.02200 | |||||||||
Debt Instrument, Converted Amount | $ | $ 17,240 | |||||||||
Debt Conversion #38 | ||||||||||
Date of Issuance | May 27, 2015 | |||||||||
Common Stock, shares issued | 701,801 | |||||||||
Common Stock, price per share | $ / shares | $ 0.01933 | |||||||||
Debt Instrument, Converted Amount | $ | $ 13,568 | |||||||||
Debt Conversion #39 | ||||||||||
Date of Issuance | May 29, 2015 | |||||||||
Common Stock, shares issued | 882,353 | |||||||||
Common Stock, price per share | $ / shares | $ 0.01700 | |||||||||
Debt Instrument, Converted Amount | $ | $ 15,000 | |||||||||
Debt Conversion #40 | ||||||||||
Date of Issuance | Jun. 11, 2015 | |||||||||
Common Stock, shares issued | 942,609 | |||||||||
Common Stock, price per share | $ / shares | $ 0.01050 | |||||||||
Debt Instrument, Converted Amount | $ | $ 9,897 | |||||||||
Debt Conversion #41 | ||||||||||
Date of Issuance | Jun. 16, 2015 | |||||||||
Common Stock, shares issued | 1,175,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.01200 | |||||||||
Debt Instrument, Converted Amount | $ | $ 14,100 | |||||||||
Debt Conversion #42 | ||||||||||
Date of Issuance | Jun. 16, 2015 | |||||||||
Common Stock, shares issued | 1,130,417 | |||||||||
Common Stock, price per share | $ / shares | $ 0.01200 | |||||||||
Debt Instrument, Converted Amount | $ | $ 13,565 | |||||||||
Debt Conversion #43 | ||||||||||
Date of Issuance | Apr. 8, 2015 | |||||||||
Common Stock, shares issued | 454,545 | |||||||||
Common Stock, price per share | $ / shares | $ 0.04400 | |||||||||
Debt Instrument, Converted Amount | $ | $ 20,001 | |||||||||
Debt Conversion #44 | ||||||||||
Date of Issuance | Jun. 22, 2015 | |||||||||
Common Stock, shares issued | 1,235,833 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00600 | |||||||||
Debt Instrument, Converted Amount | $ | $ 7,415 | |||||||||
Debt Conversion #45 | ||||||||||
Date of Issuance | Jun. 22, 2015 | |||||||||
Common Stock, shares issued | 2,479,924 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00580 | |||||||||
Debt Instrument, Converted Amount | $ | $ 14,384 | |||||||||
Debt Conversion #46 | ||||||||||
Date of Issuance | Jun. 23, 2015 | |||||||||
Common Stock, shares issued | 1,292,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00600 | |||||||||
Debt Instrument, Converted Amount | $ | $ 7,752 | |||||||||
Debt Conversion #47 | ||||||||||
Date of Issuance | Sep. 16, 2015 | |||||||||
Common Stock, shares issued | 1,772,033 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00450 | |||||||||
Debt Instrument, Converted Amount | $ | $ 7,974 | |||||||||
Debt Conversion #48 | ||||||||||
Date of Issuance | Sep. 28, 2015 | |||||||||
Common Stock, shares issued | 1,666,667 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00600 | |||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | |||||||||
Debt Conversion #49 | ||||||||||
Date of Issuance | Sep. 29, 2015 | |||||||||
Common Stock, shares issued | 1,770,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00600 | |||||||||
Debt Instrument, Converted Amount | $ | $ 10,620 | |||||||||
Debt Conversion #50 | ||||||||||
Date of Issuance | Oct. 7, 2015 | |||||||||
Common Stock, shares issued | 375,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0060 | |||||||||
Debt Instrument, Converted Amount | $ | $ 2,250 | |||||||||
Debt Conversion #51 | ||||||||||
Date of Issuance | Oct. 7, 2015 | |||||||||
Common Stock, shares issued | 1,400,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0060 | |||||||||
Debt Instrument, Converted Amount | $ | $ 8,400 | |||||||||
Debt Conversion #52 | ||||||||||
Date of Issuance | Oct. 19, 2015 | |||||||||
Common Stock, shares issued | 1,620,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0060 | |||||||||
Debt Instrument, Converted Amount | $ | $ 9,720 | |||||||||
Debt Conversion #53 | ||||||||||
Date of Issuance | Nov. 2, 2015 | |||||||||
Common Stock, shares issued | 1,966,124 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00225 | |||||||||
Debt Instrument, Converted Amount | $ | $ 4,424 | |||||||||
Debt Conversion #54 | ||||||||||
Date of Issuance | Nov. 23, 2015 | |||||||||
Common Stock, shares issued | 1,666,667 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0060 | |||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | |||||||||
Debt Conversion #55 | ||||||||||
Date of Issuance | Nov. 30, 2015 | |||||||||
Common Stock, shares issued | 2,591,323 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00650 | |||||||||
Debt Instrument, Converted Amount | $ | $ 16,844 | |||||||||
Debt Conversion #56 | ||||||||||
Date of Issuance | Dec. 9, 2015 | |||||||||
Common Stock, shares issued | 775,991 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00225 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,746 | |||||||||
Debt Conversion #57 | ||||||||||
Date of Issuance | Dec. 17, 2015 | |||||||||
Common Stock, shares issued | 919,319 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00580 | |||||||||
Debt Instrument, Converted Amount | $ | $ 5,332 | |||||||||
Debt Conversion #58 | ||||||||||
Date of Issuance | Dec. 28, 2015 | |||||||||
Common Stock, shares issued | 596,200 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00225 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,341 | |||||||||
Debt Conversion #59 | ||||||||||
Date of Issuance | Dec. 28, 2015 | |||||||||
Common Stock, shares issued | 2,950,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00600 | |||||||||
Debt Instrument, Converted Amount | $ | $ 17,700 | |||||||||
Debt Conversion #60 | ||||||||||
Date of Issuance | Dec. 28, 2015 | |||||||||
Common Stock, shares issued | 2,384,167 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00600 | |||||||||
Debt Instrument, Converted Amount | $ | $ 14,305 | |||||||||
Debt Conversion #61 | ||||||||||
Date of Issuance | Dec. 28, 2015 | |||||||||
Common Stock, shares issued | 2,579,916 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00580 | |||||||||
Debt Instrument, Converted Amount | $ | $ 14,963 | |||||||||
Debt Conversion #62 | ||||||||||
Date of Issuance | Dec. 29, 2015 | |||||||||
Common Stock, shares issued | 1,399,167 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00600 | |||||||||
Debt Instrument, Converted Amount | $ | $ 8,395 | |||||||||
Debt Conversion #63 | ||||||||||
Date of Issuance | Dec. 29, 2015 | |||||||||
Common Stock, shares issued | 1,278,333 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00600 | |||||||||
Debt Instrument, Converted Amount | $ | $ 7,670 | |||||||||
Debt Conversion #64 | ||||||||||
Date of Issuance | Dec. 30, 2015 | |||||||||
Common Stock, shares issued | 2,956,248 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00225 | |||||||||
Debt Instrument, Converted Amount | $ | $ 6,651 | |||||||||
2013 Stock Option Plan Amendment | ||||||||||
Date of Agreement | Jan. 12, 2015 | |||||||||
Options granted, number of shares | 672,533 | |||||||||
Exercise price | $ / shares | $ 0.17 | |||||||||
Stock-based compensation | $ | $ 50,448 | |||||||||
2013 Stock Option Plan Amdt #2 | ||||||||||
Date of Agreement | Apr. 6, 2015 | |||||||||
Options granted, number of shares | 2,712,535 | |||||||||
Exercise price | $ / shares | $ 0.08 | |||||||||
Stock-based compensation | $ | $ 9,316 | |||||||||
2013 Stock Option Plan Amdt #3 | ||||||||||
Date of Agreement | Aug. 4, 2015 | |||||||||
Options granted, number of shares | 3,712,535 | |||||||||
Exercise price | $ / shares | $ 0.02 | |||||||||
Stock-based compensation | $ | $ 47,463 | |||||||||
Debt Conversion #65 | ||||||||||
Date of Issuance | Jan. 4, 2016 | |||||||||
Common Stock, shares issued | 3,223,213 | |||||||||
Common Stock, price per share | $ / shares | $ 0.006 | |||||||||
Debt Instrument, Converted Amount | $ | $ 19,339 | |||||||||
Debt Conversion #66 | ||||||||||
Date of Issuance | Jan. 5, 2016 | |||||||||
Common Stock, shares issued | 3,603,227 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00225 | |||||||||
Debt Instrument, Converted Amount | $ | $ 8,107 | |||||||||
Debt Conversion #67 | ||||||||||
Date of Issuance | Jan. 6, 2016 | |||||||||
Common Stock, shares issued | 2,678,333 | |||||||||
Common Stock, price per share | $ / shares | $ 0.006 | |||||||||
Debt Instrument, Converted Amount | $ | $ 16,070 | |||||||||
Debt Conversion #68 | ||||||||||
Date of Issuance | Jan. 6, 2016 | |||||||||
Common Stock, shares issued | 2,861,607 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0058 | |||||||||
Debt Instrument, Converted Amount | $ | $ 16,597 | |||||||||
Debt Conversion #69 | ||||||||||
Date of Issuance | Feb. 16, 2016 | |||||||||
Common Stock, shares issued | 4,220,400 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00034 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,424 | |||||||||
Debt Conversion #70 | ||||||||||
Date of Issuance | Feb. 17, 2016 | |||||||||
Common Stock, shares issued | 8,443,272 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00152 | |||||||||
Debt Instrument, Converted Amount | $ | $ 12,800 | |||||||||
Debt Conversion #71 | ||||||||||
Date of Issuance | Feb. 23, 2016 | |||||||||
Common Stock, shares issued | 4,218,182 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0011 | |||||||||
Debt Instrument, Converted Amount | $ | $ 4,640 | |||||||||
Debt Conversion #72 | ||||||||||
Date of Issuance | Feb. 23, 2016 | |||||||||
Common Stock, shares issued | 4,200,871 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00073 | |||||||||
Debt Instrument, Converted Amount | $ | $ 3,086 | |||||||||
Debt Conversion #73 | ||||||||||
Date of Issuance | Feb. 24, 2016 | |||||||||
Common Stock, shares issued | 4,419,970 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00034 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,492 | |||||||||
Debt Conversion #74 | ||||||||||
Date of Issuance | Feb. 25, 2016 | |||||||||
Common Stock, shares issued | 2,638,987 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00114 | |||||||||
Debt Instrument, Converted Amount | $ | $ 3,000 | |||||||||
Debt Conversion #75 | ||||||||||
Date of Issuance | Feb. 25, 2016 | |||||||||
Common Stock, shares issued | 4,218,182 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0011 | |||||||||
Debt Instrument, Converted Amount | $ | $ 4,640 | |||||||||
Debt Conversion #76 | ||||||||||
Date of Issuance | Mar. 1, 2016 | |||||||||
Common Stock, shares issued | 5,834,458 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00022 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,313 | |||||||||
Debt Conversion #77 | ||||||||||
Date of Issuance | Mar. 2, 2016 | |||||||||
Common Stock, shares issued | 5,831,642 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00079 | |||||||||
Debt Instrument, Converted Amount | $ | $ 4,600 | |||||||||
Debt Conversion #78 | ||||||||||
Date of Issuance | Mar. 2, 2016 | |||||||||
Common Stock, shares issued | 2,586,410 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00064 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,650 | |||||||||
Debt Conversion #79 | ||||||||||
Date of Issuance | Mar. 2, 2016 | |||||||||
Common Stock, shares issued | 11,650,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0008 | |||||||||
Debt Instrument, Converted Amount | $ | $ 9,332 | |||||||||
Debt Conversion #80 | ||||||||||
Date of Issuance | Mar. 7, 2016 | |||||||||
Common Stock, shares issued | 6,546,292 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00043 | |||||||||
Debt Instrument, Converted Amount | $ | $ 2,799 | |||||||||
Debt Conversion #81 | ||||||||||
Date of Issuance | Mar. 11, 2016 | |||||||||
Common Stock, shares issued | 4,147,500 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00046 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,924 | |||||||||
Debt Conversion #82 | ||||||||||
Date of Issuance | Mar. 14, 2016 | |||||||||
Common Stock, shares issued | 7,125,777 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00032 | |||||||||
Debt Instrument, Converted Amount | $ | $ 2,245 | |||||||||
Debt Conversion #83 | ||||||||||
Date of Issuance | Mar. 15, 2016 | |||||||||
Common Stock, shares issued | 7,454,098 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00045 | |||||||||
Debt Instrument, Converted Amount | $ | $ 3,329 | |||||||||
Debt Conversion #84 | ||||||||||
Date of Issuance | Mar. 15, 2016 | |||||||||
Common Stock, shares issued | 11,450,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00046 | |||||||||
Debt Instrument, Converted Amount | $ | $ 5,210 | |||||||||
Debt Conversion #85 | ||||||||||
Date of Issuance | Mar. 22, 2016 | |||||||||
Common Stock, shares issued | 8,957,888 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00027 | |||||||||
Debt Instrument, Converted Amount | $ | $ 2,419 | |||||||||
Debt Conversion #86 | ||||||||||
Date of Issuance | Mar. 22, 2016 | |||||||||
Common Stock, shares issued | 7,200,486 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00033 | |||||||||
Debt Instrument, Converted Amount | $ | $ 2,367 | |||||||||
Debt Conversion #87 | ||||||||||
Date of Issuance | Mar. 22, 2016 | |||||||||
Common Stock, shares issued | 11,682,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00046 | |||||||||
Debt Instrument, Converted Amount | $ | $ 5,315 | |||||||||
Debt Conversion #88 | ||||||||||
Date of Issuance | Mar. 28, 2016 | |||||||||
Common Stock, shares issued | 8,958,779 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00022 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,986 | |||||||||
Debt Conversion #89 | ||||||||||
Date of Issuance | Apr. 1, 2016 | |||||||||
Common Stock, shares issued | 9,766,311 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000225 | |||||||||
Debt Instrument, Converted Amount | $ | $ 2,197 | |||||||||
Debt Conversion #90 | ||||||||||
Date of Issuance | Apr. 4, 2016 | |||||||||
Common Stock, shares issued | 17,250,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000281 | |||||||||
Debt Instrument, Converted Amount | $ | $ 4,847 | |||||||||
Debt Conversion #91 | ||||||||||
Date of Issuance | Apr. 7, 2016 | |||||||||
Common Stock, shares issued | 9,722,222 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000180 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,750 | |||||||||
Debt Conversion #92 | ||||||||||
Date of Issuance | Apr. 14, 2016 | |||||||||
Common Stock, shares issued | 19,250,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000216 | |||||||||
Debt Instrument, Converted Amount | $ | $ 4,158 | |||||||||
Debt Conversion #93 | ||||||||||
Date of Issuance | Apr. 15, 2016 | |||||||||
Common Stock, shares issued | 9,766,222 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000135 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,318 | |||||||||
Debt Conversion #94 | ||||||||||
Date of Issuance | Apr. 26, 2016 | |||||||||
Common Stock, shares issued | 12,629,776 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000135 | |||||||||
Debt Instrument, Converted Amount | $ | $ 1,705 | |||||||||
Debt Conversion #95 | ||||||||||
Date of Issuance | May 4, 2016 | |||||||||
Common Stock, shares issued | 9,718,025 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000213 | |||||||||
Debt Instrument, Converted Amount | $ | $ 2,067 | |||||||||
Debt Conversion #96 | ||||||||||
Date of Issuance | May 31, 2016 | |||||||||
Common Stock, shares issued | 4,600,055 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000180 | |||||||||
Debt Instrument, Converted Amount | $ | $ 828 | |||||||||
Debt Conversion #97 | ||||||||||
Date of Issuance | Jun. 2, 2016 | |||||||||
Common Stock, shares issued | 30,000,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000304 | |||||||||
Debt Instrument, Converted Amount | $ | $ 9,120 | |||||||||
Debt Conversion #98 | ||||||||||
Date of Issuance | Jun. 2, 2016 | |||||||||
Common Stock, shares issued | 29,340,333 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000150 | |||||||||
Debt Instrument, Converted Amount | $ | $ 4,401 | |||||||||
Debt Conversion #99 | ||||||||||
Date of Issuance | Jun. 14, 2016 | |||||||||
Common Stock, shares issued | 29,235,900 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000200 | |||||||||
Debt Instrument, Converted Amount | $ | $ 5,847 | |||||||||
Debt Conversion #100 | ||||||||||
Date of Issuance | Jun. 17, 2016 | |||||||||
Common Stock, shares issued | 28,456,150 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000200 | |||||||||
Debt Instrument, Converted Amount | $ | $ 5,691 | |||||||||
Debt Conversion #101 | ||||||||||
Date of Issuance | Jun. 29, 2017 | |||||||||
Common Stock, shares issued | 21,270,355 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000309 | |||||||||
Debt Instrument, Converted Amount | $ | $ 6,580 | |||||||||
Asset Assign Agmt #2 | ||||||||||
Date of Agreement | Oct. 6, 2014 | |||||||||
Common Stock, shares issued | 2,207,920 | |||||||||
Deemed Dividend | $ | $ 7,822,235 | |||||||||
Asset Assign Agmt | ||||||||||
Date of Agreement | Jul. 18, 2015 | |||||||||
Common Stock, shares issued | 827,670 | |||||||||
Series A Preferred Stock, shares issued | 6,000,000 | |||||||||
Shares Issued, Value | $ | $ 123,973 | |||||||||
Sale Agmt | ||||||||||
Shares agreed to cancel | 2,625,210 | |||||||||
Shares returned to treasury | 5,002,554 | |||||||||
Date of Agreement | Jul. 19, 2013 | |||||||||
Consultant | ||||||||||
Shares issued for services | 25,000 | |||||||||
Shares issued for services, value | $ | $ 300,000 | |||||||||
Exercise Date | May 7, 2014 | |||||||||
Stock Deposits | ||||||||||
Common Stock, shares issued | 14,690 | |||||||||
Shares Issued, Value | $ | $ 147,050 | |||||||||
Exercise Date | Jun. 16, 2014 | |||||||||
Legal Services | ||||||||||
Shares issued for services | 10,000 | |||||||||
Shares issued for services, value | $ | $ 60,000 | |||||||||
Exercise Date | Jul. 1, 2014 | |||||||||
Loss on issuance of stock | $ | $ (30,000) | |||||||||
CEO | ||||||||||
Date of Agreement | Oct. 6, 2014 | |||||||||
Shares issued for services | 80,000 | |||||||||
Attorney | ||||||||||
Date of Agreement | Oct. 6, 2014 | |||||||||
Shares issued for services | 40,000 | |||||||||
Attorney & CEO | ||||||||||
Shares issued for services, value | $ | $ 429,600 | |||||||||
Vendor | ||||||||||
Date of Agreement | Nov. 19, 2014 | |||||||||
Shares issued for services | 5,000 | |||||||||
Shares issued for services, value | $ | $ 6,450 | |||||||||
Investment Agmt | ||||||||||
Date of Agreement | Aug. 13, 2014 | |||||||||
Shares issued for services | 799,619 | |||||||||
Shares issued for services, value | $ | $ 220,000 | |||||||||
Sale of Stock #1 | ||||||||||
Issuance of common stock for cash, shares | 100,381 | |||||||||
Issuance of common stock for cash, amount | $ | $ 5,405 | |||||||||
Date of Issuance | Apr. 22, 2015 | |||||||||
Sale of Stock #2 | ||||||||||
Issuance of common stock for cash, shares | 1,542,455 | |||||||||
Issuance of common stock for cash, amount | $ | $ 10,797 | |||||||||
Date of Issuance | Jun. 25, 2015 | |||||||||
Sale of Stock #3 | ||||||||||
Issuance of common stock for cash, shares | 1,619,423 | |||||||||
Issuance of common stock for cash, amount | $ | $ 11,336 | |||||||||
Date of Issuance | Jul. 7, 2015 | |||||||||
Sale of Stock #4 | ||||||||||
Issuance of common stock for cash, shares | 1,439,282 | |||||||||
Issuance of common stock for cash, amount | $ | $ 10,075 | |||||||||
Date of Issuance | Jul. 15, 2015 | |||||||||
Sale of Stock #5 | ||||||||||
Issuance of common stock for cash, shares | 1,648,840 | |||||||||
Issuance of common stock for cash, amount | $ | $ 11,542 | |||||||||
Date of Issuance | Oct. 27, 2015 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) | Jun. 30, 2016USD ($) |
Accounting Policies [Abstract] | |
Monthly Rent | $ 2,800 |
Subsequent Event (Details Narra
Subsequent Event (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |||
Jun. 30, 2016 | Jun. 30, 2015 | Mar. 31, 2016 | Sep. 06, 2013 | Sep. 05, 2013 | |
Common Stock, Shares Authorized | 4,000,000,000 | 4,000,000,000 | 375,030,000 | 900,000 | |
Debt Instrument, Converted Amount | $ 50,510 | $ 449,825 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 3,449 | ||||
Common Stock, shares issued | 14,690 | ||||
Convertible Prom Note #35 | |||||
Date of Agreement | Jul. 7, 2016 | ||||
Convertible Note | $ 58,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jul. 7, 2017 |